biotochina

Vol.57, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

YAFO Client | Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare’s New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

Protected: YAFO Client | Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare’s New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

insight monthly alert

2025 June-YAFO Global Biopharma Transactions Report 雅法全球生物医药交易月报

Vol.56, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

Vol.55, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报